We sat down with Nina Capital‘s Sebastian Anastassiou to talk about HealthTech, Digital Therapeutics, and the impact of the pandemic on startup investing in Healthcare.
A vision for the future inspires Nina Capital’s investment approach. Data derived through computing, IoT, and sensor technologies deliver meaningful insight for improving health and providing care. They are interested in all specialties and are especially committed to addressing oncology, aging, and cardiovascular needs. This approach is based upon the Stanford-born methodology of health technology innovation known as Biodesign, proven to de-risk the process of new health technology venture creation.
Sebastion’s expertise is in commercializing early-stage biomedical and healthcare research, intellectual property management, technology transfer, and venture capital within the life sciences and healthcare industry. He previously managed a portfolio of biomedical and healthcare technologies from ideation stages to proof-of-concept and eventual commercialization through out-licensing and spinout company creation. He has experienced both sides of the venture capital table by pitching to several VCs for £M+ investments and collaborating with a VCT on a co-managed university venture fund.
“We have a vision for the future in which data derived through computing, IoT, and sensor technologies deliver meaningful insight for improving health and preventing disease. We believe the creation of new businesses is built on an in-depth understanding of healthcare system participants’ complex network and marrying that with advanced data science and IT-enabled products and services. We look for and support European founders determined to effectively and efficiently serve these participants on this continent and internationally. We are especially committed to addressing needs in the areas of oncology, aging, and cardiovascular. We see our sweet spot at seeding founders and helping them ready for series A, co-investing alongside other European and international firms.”